NASDAQ:SGYP - Synergy Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.69 -0.03 (-1.74 %)
(As of 09/21/2018 04:00 PM ET)
Previous Close$1.72
Today's Range$1.66 - $1.75
52-Week Range$1.42 - $3.57
Volume6.38 million shs
Average Volume3.89 million shs
Market Capitalization$424.06 million
P/E Ratio-1.71
Dividend YieldN/A
Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome. The company also develops dolcanatide to treat mild-to-moderate ulcerative colitis. It has a licensing agreement with Cipher Pharmaceuticals Inc. to develop, market, distribute, and sell TRULANCE in Canada. Synergy Pharmaceuticals Inc. is headquartered in New York, New York.

Receive SGYP News and Ratings via Email

Sign-up to receive the latest news and ratings for SGYP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity Ratio-1.82
Current Ratio2.83
Quick Ratio2.31


Trailing P/E Ratio-1.71
Forward P/E Ratio-3.02
P/E GrowthN/A

Sales & Book Value

Annual Sales$16.82 million
Price / Sales24.92
Cash FlowN/A
Price / CashN/A
Book Value($0.02) per share
Price / Book-84.50


EPS (Most Recent Fiscal Year)($1.02)
Net Income$-224,330,000.00
Net Margins-430.21%
Return on Equity-652.66%
Return on Assets-115.03%


Outstanding Shares247,990,000
Market Cap$424.06 million

Synergy Pharmaceuticals (NASDAQ:SGYP) Frequently Asked Questions

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

How were Synergy Pharmaceuticals' earnings last quarter?

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) released its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.12) EPS for the quarter, beating the Zacks' consensus estimate of ($0.15) by $0.03. The biopharmaceutical company had revenue of $12.25 million for the quarter, compared to analyst estimates of $10.20 million. Synergy Pharmaceuticals had a negative net margin of 430.21% and a negative return on equity of 652.66%. View Synergy Pharmaceuticals' Earnings History.

When is Synergy Pharmaceuticals' next earnings date?

Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November, 8th 2018. View Earnings Estimates for Synergy Pharmaceuticals.

What price target have analysts set for SGYP?

7 brokers have issued 1-year target prices for Synergy Pharmaceuticals' stock. Their forecasts range from $7.00 to $13.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $9.40 in the next twelve months. This suggests a possible upside of 456.2% from the stock's current price. View Analyst Price Targets for Synergy Pharmaceuticals.

What is the consensus analysts' recommendation for Synergy Pharmaceuticals?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synergy Pharmaceuticals in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Synergy Pharmaceuticals.

Are investors shorting Synergy Pharmaceuticals?

Synergy Pharmaceuticals saw a increase in short interest in August. As of August 31st, there was short interest totalling 58,772,867 shares, an increase of 0.2% from the August 15th total of 58,629,834 shares. Based on an average trading volume of 2,129,614 shares, the short-interest ratio is presently 27.6 days. Currently, 23.8% of the company's stock are sold short. View Synergy Pharmaceuticals' Current Options Chain.

Who are some of Synergy Pharmaceuticals' key competitors?

Who are Synergy Pharmaceuticals' key executives?

Synergy Pharmaceuticals' management team includes the folowing people:
  • Dr. Gary S. Jacob, Exec. Chairman (Age 71)
  • Mr. Troy Hamilton Pharm.D., CEO & Director (Age 46)
  • Mr. Gary G. Gemignani, Exec. VP & CFO (Age 53)
  • Dr. Patrick H. Griffin, Exec. VP & Chief Medical Officer (Age 63)
  • Mr. Marino Garcia, Exec. VP & Chief Strategy Officer (Age 51)

Has Synergy Pharmaceuticals been receiving favorable news coverage?

Media headlines about SGYP stock have trended somewhat positive on Saturday, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Synergy Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned media coverage about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View Recent Headlines for Synergy Pharmaceuticals.

Who are Synergy Pharmaceuticals' major shareholders?

Synergy Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.81%), Hikari Power Ltd (0.93%), Schwab Charles Investment Management Inc. (0.53%), Bank of New York Mellon Corp (0.43%), Bank of New York Mellon Corp (0.43%) and Bank of America Corp DE (0.10%). Company insiders that own Synergy Pharmaceuticals stock include Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Which major investors are selling Synergy Pharmaceuticals stock?

SGYP stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp and Bank of New York Mellon Corp. View Insider Buying and Selling for Synergy Pharmaceuticals.

Which major investors are buying Synergy Pharmaceuticals stock?

SGYP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Bank of America Corp DE, Hikari Power Ltd, Chicago Equity Partners LLC, Schwab Charles Investment Management Inc., Mackay Shields LLC and Metropolitan Life Insurance Co. NY. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

How do I buy shares of Synergy Pharmaceuticals?

Shares of SGYP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Synergy Pharmaceuticals' stock price today?

One share of SGYP stock can currently be purchased for approximately $1.69.

How big of a company is Synergy Pharmaceuticals?

Synergy Pharmaceuticals has a market capitalization of $424.06 million and generates $16.82 million in revenue each year. The biopharmaceutical company earns $-224,330,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Synergy Pharmaceuticals employs 313 workers across the globe.

How can I contact Synergy Pharmaceuticals?

Synergy Pharmaceuticals' mailing address is 420 LEXINGTON AVENUE SUITE 2012, NEW YORK NY, 10170. The biopharmaceutical company can be reached via phone at 212-297-0020 or via email at [email protected]

MarketBeat Community Rating for Synergy Pharmaceuticals (NASDAQ SGYP)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  604 (Vote Outperform)
Underperform Votes:  283 (Vote Underperform)
Total Votes:  887
MarketBeat's community ratings are surveys of what our community members think about Synergy Pharmaceuticals and other stocks. Vote "Outperform" if you believe SGYP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGYP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/22/2018 by Staff

Featured Article: Moving Average (MA)

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel